ArticleCureus2025
Racemose Neurocysticercosis Presenting As Vasculitic Infarct and Obstructive Hydrocephalus: A Rare Presentation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Racemose neurocysticercosis (NCC) is a rare and aggressive form of parasitic infection that primarily involves the subarachnoid space. It can lead to serious complications such as hydrocephalus and ischemic stroke due to vasculitis. Early recognition of this condition is essential for preventing long-term neurological damage. This report discusses a case of a 68-year-old male who presented with sudden onset right-sided hemiplegia and facial palsy despite having no previous comorbidities. Imaging studies revealed extraparenchymal cystic lesions consistent with racemose NCC, leading to obstructive hydrocephalus and stroke. The patient was treated with a combination of albendazole, praziquantel, and dexamethasone. Following three weeks of therapy, he demonstrated marked clinical improvement and was subsequently discharged with instructions for follow-up care. This case highlights the critical need for timely diagnosis and management of racemose NCC to improve neurological outcomes. Prompt treatment using antiparasitic agents and steroids can play a pivotal role in facilitating recovery and minimizing complications. Recognizing racemose NCC as a potential cause of stroke and hydrocephalus in endemic areas is vital for early intervention and enhanced patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.